
    
      A total of 10 patients with moderate to severe psoriasis who are currently using adalimumab
      for at least 12 weeks but have a PGA of mild or worse will be transitioned to etanercept 50
      mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an
      additional 12 weeks.
    
  